🇺🇸 FDA
Patent

US 8178109

Compositions and methods of use for MGD-CSF in disease treatment

granted A61KA61K38/00A61P

Quick answer

US patent 8178109 (Compositions and methods of use for MGD-CSF in disease treatment) held by Five Prime Therapeutics, Inc. expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K38/00, A61P, A61P1/04, A61P1/14